Exicure 과거 수익 실적
과거 기준 확인 0/6
Exicure has been growing earnings at an average annual rate of 14.9%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 12.5% per year.
주요 정보
14.9%
수익 성장률
29.8%
EPS 성장률
Biotechs 산업 성장 | 17.0% |
매출 성장률 | 12.5% |
자기자본 수익률 | -506.6% |
순이익 | -1,634.4% |
최근 수익 업데이트 | 30 Jun 2024 |
최근 과거 실적 업데이트
Recent updates
Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding
Aug 29Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities
Sep 26Exicure Q2 GAAP loss per share narrows, revenue up
Aug 15Exicure regains compliance with Nasdaq's minimum bid price requirement
Jul 20Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance
Jun 29Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?
Aug 25Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?
Mar 10수익 및 비용 분석
Exicure 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Jun 24 | 1 | -8 | 6 | 0 |
31 Mar 24 | 1 | -13 | 11 | 0 |
31 Dec 23 | 0 | -17 | 13 | 0 |
30 Sep 23 | 22 | 3 | 13 | 0 |
30 Jun 23 | 24 | 3 | 13 | 0 |
31 Mar 23 | 26 | 1 | 11 | 0 |
31 Dec 22 | 29 | -3 | 11 | 0 |
30 Sep 22 | 9 | -35 | 13 | 0 |
30 Jun 22 | 3 | -53 | 13 | 0 |
31 Mar 22 | 1 | -60 | 13 | 0 |
31 Dec 21 | 0 | -64 | 13 | 0 |
30 Sep 21 | -2 | -63 | 12 | 0 |
30 Jun 21 | 4 | -48 | 11 | 0 |
31 Mar 21 | 8 | -38 | 10 | 0 |
31 Dec 20 | 17 | -25 | 10 | 0 |
30 Sep 20 | 17 | -22 | 9 | 0 |
30 Jun 20 | 15 | -19 | 9 | 0 |
31 Mar 20 | 10 | -20 | 9 | 0 |
31 Dec 19 | 1 | -26 | 9 | 0 |
30 Sep 19 | 1 | -21 | 8 | 0 |
30 Jun 19 | 1 | -21 | 8 | 0 |
31 Mar 19 | 0 | -22 | 8 | 0 |
31 Dec 18 | 0 | -22 | 8 | 0 |
30 Sep 18 | 2 | -21 | 8 | 0 |
30 Jun 18 | 5 | -18 | 8 | 0 |
31 Mar 18 | 7 | -14 | 8 | 0 |
31 Dec 17 | 10 | -11 | 7 | 0 |
30 Sep 17 | 8 | -13 | 6 | 0 |
30 Jun 17 | 6 | -15 | 5 | 0 |
31 Mar 17 | 3 | -16 | 4 | 0 |
31 Dec 16 | 1 | -17 | 4 | 0 |
31 Dec 15 | 2 | -6 | 5 | 0 |
양질의 수익: XCUR is currently unprofitable.
이익 마진 증가: XCUR is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: XCUR is unprofitable, but has reduced losses over the past 5 years at a rate of 14.9% per year.
성장 가속화: Unable to compare XCUR's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: XCUR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
자기자본 수익률
높은 ROE: XCUR has a negative Return on Equity (-506.63%), as it is currently unprofitable.